Skip Navigation
Search

News

ICB&DD Welcomes New Members:  Drs. Anissa Abi-Dargham, Stuti Sharma and Markus Riessland

aaDr. Anissa Abi-Dargham, Distinguished Professor and The Lourie Endowed Chair, Department of Psychiatry and Behavioral Health, Stony Brook Renaissance School of Medicine

ssDr. Stuti Sharma, Assistant Professor, Department of Biochemistry and Cell Biology,  Stony Brook Renaissance School of Medicine

mrDr. Markus Riessland , Assistant Professor, Department of Neurobiology and Behavior,  Stony Brook Renaissance School of Medicine

ICB&DD 17th Annual Symposium "Frontiers in Chemical Biology and Drug Discovery" at the SAC (read more)

 
 

gp

From SBU news Drug Discoveries, Students Research Showcased at ICB&DD Symposium  

ICB&DD welcomes New Members: Drs. Matthew Parker and Jeffrey Lipshultz

mpDr. Matthew Parker, Assistant Professor, Department of Psychiatry and Behavioral Health. Stony Brook Renaissance School of Medicine

 

jlDr. Jeffrey Lipshultz, Assistant Professor, Department of Chemistry.

(read more)
jjCongratulations to ICB&DD Member,Dr. Jingfang Ju, Professor in the Department of Pathology for being on the cover of the International Journal of Oncology (Int. J. Oncol.) for the month of July 2023. Int. J. Oncol.  is an international journal devoted to oncology research and cancer treatment.  (See more)

Dr. John Hartwig Receives The Ojima Distinguished Lectureship Award in Chemistry

jhDr. John Hartwig gave a lecture at the Ojima Distinguished Lectureship Award in Chemistry on May 5 at the Wang Center, SBU.

(Read more)

TVM Capital Life Science (TVM) is committing up to $24 million for a development program to advance NE-DHA-SBT-1214, Dr. Iwao Ojima's compound, to market for the treatatment of colorectal cancer and other solid tumors.  TVM(read more one) (read more two)
ICB&DD 16th Annual Symposium

Sym grp

First full in-person Annual Symposium since 2019 (Read more)

 

 More News

Message from the Director

oDr. Iwao Ojima, Distinguished Professor and Director, ICB&DD 

Welcome to the Institute of Chemical Biology & Drug Discovery

The primary objective of ICB&DD is to establish a world-class “Center of Excellence” in chemical biology and drug discovery at Stony Brook.  The rapid and impressive advancement of chemical biology in the last decades clearly demonstrated that solutions for vast majority of medical problems rely on the understanding of the molecular basis of diseases, therapeutic targets, drug actions, and drug resistance.  ICB&DD promotes highly productive interdisciplinary and multidisciplinary research bridging the West, East and South campuses as well as Brookhaven National Laboratory to attack major and significant biomedical problems to find solutions including the discovery of novel therapeutic drugs. ICB&DD significantly contributes to the advancement of a truly comprehensive biomedical research enterprise from molecular science to clinic at Stony Brook.

ICB&DD Events

ICB&DD 2023 SYMPOSIUM 

symp

Poster Session 
SUBMIT POSTER HERE